Silence Therapeutics RNAi Lead Compound Atu027 Successfully Completes 28-Day Toxicology Studies
12-Sep-2007 -
Silence Therapeutics plc announced that its lead compound, Atu027, has successfully completed pre-clinical, 28-day toxicology studies. Silence Therapeutics has identified a dose range for Atu027, a systemically delivered RNAi compound, at which additional pre-clinical studies will be conducted ...
chemistry
clinical trials
toxicology